PL2844277T3 - Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD) - Google Patents

Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD)

Info

Publication number
PL2844277T3
PL2844277T3 PL13726296T PL13726296T PL2844277T3 PL 2844277 T3 PL2844277 T3 PL 2844277T3 PL 13726296 T PL13726296 T PL 13726296T PL 13726296 T PL13726296 T PL 13726296T PL 2844277 T3 PL2844277 T3 PL 2844277T3
Authority
PL
Poland
Prior art keywords
adhd
prevention
treatment
attention deficit
hyperactivity disorder
Prior art date
Application number
PL13726296T
Other languages
English (en)
Other versions
PL2844277T5 (pl
Inventor
Riu Carlos Duelo
Riu Juan José Duelo
Original Assignee
Dr Healthcare España, S. L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2844277(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Healthcare España, S. L. filed Critical Dr Healthcare España, S. L.
Publication of PL2844277T3 publication Critical patent/PL2844277T3/pl
Publication of PL2844277T5 publication Critical patent/PL2844277T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03006—Amine oxidase (copper-containing)(1.4.3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL13726296T 2012-04-18 2013-04-18 Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD) PL2844277T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201230578A ES2426539B1 (es) 2012-04-18 2012-04-18 Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
EP13726296.0A EP2844277B2 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)
PCT/IB2013/053068 WO2013156955A1 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)

Publications (2)

Publication Number Publication Date
PL2844277T3 true PL2844277T3 (pl) 2017-09-29
PL2844277T5 PL2844277T5 (pl) 2020-07-13

Family

ID=48539331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13726296T PL2844277T5 (pl) 2012-04-18 2013-04-18 Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD)

Country Status (11)

Country Link
US (1) US9795654B2 (pl)
EP (1) EP2844277B2 (pl)
CN (1) CN104284672A (pl)
DK (1) DK2844277T3 (pl)
ES (2) ES2426539B1 (pl)
HU (1) HUE032712T2 (pl)
MX (1) MX361227B (pl)
PL (1) PL2844277T5 (pl)
PT (1) PT2844277T (pl)
RU (1) RU2660344C2 (pl)
WO (1) WO2013156955A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12201676B2 (en) 2011-03-18 2025-01-21 Dr Healthcare España, S.L. Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
EP4523700A1 (en) * 2023-09-14 2025-03-19 Dr Healthcare España, S. L. Diamine oxidase (dao) for use in the treatment and/or prevention of lower urinary tract symptoms (luts), overactive bladder (oab) symptoms and enuresis
EP4591876A1 (en) * 2024-01-25 2025-07-30 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment and/or prevention of sleep and circadian rhythm disorders, and cognitive impairment associated thereto

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6815177A (pl) 1968-10-24 1970-04-28
GB1313318A (en) 1969-10-07 1973-04-11 Urbin M C Pharmaceutical preparation for the treatment of hemorrhoids
FR2101095A1 (en) 1970-08-20 1972-03-31 Merieux Inst Diamine oxidase from human placenta - for treatment of hyperhistamina
FR2215944A1 (en) 1973-02-01 1974-08-30 Bellon Labor Sa Roger Extracts of human placenta - free of proteases, and contg. histaminase, kininases and monoamine-oxidases for treating allergies
GB8319540D0 (en) 1983-07-20 1983-08-24 Bovril Ltd Amine removal
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
US4725540A (en) 1984-07-09 1988-02-16 Emil Underberg Process for the preparation of amine-oxidase containing material, so produced amine-oxidase containing material
US4851243A (en) 1987-10-08 1989-07-25 Borden, Inc. Calcium fortified aseptically packaged milk
CH679582A5 (pl) * 1988-07-18 1992-03-13 Glaxo Group Ltd
JPH06502310A (ja) 1990-10-31 1994-03-17 ザ、プロクター、エンド、ギャンブル、カンパニー カルシウム強化ソース
CA2217264A1 (en) 1995-04-07 1996-10-10 Abbott Laboratories Calcium supplements and calcium containing beverages comprising vitamin d
US5855936A (en) 1997-03-21 1999-01-05 Nestec S.A. Food fortification
ES2132037B1 (es) 1997-12-04 2000-03-16 Riu Juan Jose Duelo Diadema antimigrañosa.
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
AU4361500A (en) 1999-04-20 2000-11-02 Advocare International Llc Nutritional composition for improved cognitive performance
IT1317067B1 (it) 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20030124174A1 (en) 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
US20050192290A1 (en) 2004-01-13 2005-09-01 Isaac Melamed Treatment of behavioral disorders
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
WO2006009975A2 (en) 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
AT502098B8 (de) 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
AT502850B1 (de) 2005-11-18 2007-08-15 Albert Dr Missbichler Verfahren zur bestimmung der aktivität von diaminooxidase
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
AU2008208653B2 (en) * 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
ES1064812Y (es) 2007-02-08 2007-08-01 Riu Juan Jose Duelo Dispositivo anti-migraña perfeccionado
EP2020446A1 (en) * 2007-07-31 2009-02-04 Denis Vincent Compositions and methods for detecting histamine related disorders
US20110236491A1 (en) 2010-03-25 2011-09-29 Jeannette Chantalat Topical anti-inflammatory composition
ES2387973B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
ES2388395B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica.
US12201676B2 (en) 2011-03-18 2025-01-21 Dr Healthcare España, S.L. Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
US20160024481A1 (en) 2011-03-18 2016-01-28 Dr Healthcare España, S.L. Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain
ES2388515B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Uso de la diaminooxidasa para la prevención de los síntomas de la resaca.
ES2388166B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Alimentos funcionales que contienen diaminooxidasa y sus usos.

Also Published As

Publication number Publication date
EP2844277B2 (en) 2020-03-25
EP2844277B1 (en) 2017-02-01
MX2014012636A (es) 2015-01-15
ES2621706T5 (es) 2021-01-08
US20150093430A1 (en) 2015-04-02
WO2013156955A1 (en) 2013-10-24
ES2426539A1 (es) 2013-10-23
EP2844277A1 (en) 2015-03-11
US9795654B2 (en) 2017-10-24
HUE032712T2 (en) 2017-10-30
ES2621706T3 (es) 2017-07-04
DK2844277T3 (en) 2017-04-24
CN104284672A (zh) 2015-01-14
PL2844277T5 (pl) 2020-07-13
RU2660344C2 (ru) 2018-07-05
MX361227B (es) 2018-11-29
ES2426539B1 (es) 2014-09-09
RU2014140676A (ru) 2016-06-10
PT2844277T (pt) 2017-05-12

Similar Documents

Publication Publication Date Title
IL275874A (en) Therapeutic use of adenovirus
TWI560299B (en) Surface treatment for stainless steel and housing made thereby
SG11201406192VA (en) Method for assessing the treatment of attention-deficit/hyperactivity disorder
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
ZA201401784B (en) Fluid treatment apparatus,system,and methods
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
EP2874949A4 (en) RESIDUAL WATER CONCENTRATION SYSTEM
ZA201406989B (en) Porous carbon particles for use in the treatment or prevention of liver disease
IL236145A0 (en) System and method for biological treatment of wastewater
PT2861536T (pt) Processo para a dessalinização de água
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
PT2861535T (pt) Processo para a dessalinização de água
PL2812140T3 (pl) Maszyna do toczenia i / lub dogniatania
EP2806736A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PL2844277T5 (pl) Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD)
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
PT2686004T (pt) Composição compreendendo diamina oxidase para utilização no tratamento ou prevenção da fibromialgia ou síndrome da fadiga crónica
HU1000424D0 (en) Use of radiprodil in attention deficit hyperactivity disorder
IL232897A0 (en) Phacetoperane for the treatment of attention-deficit hyperactivity disorder
GB201213486D0 (en) Quinone compounds and their uses for the treatment of cancer
TH148811B (th) ถังทำปฏิกิริยาจุลชีพและกระบวนการบำบัดน้ำทิ้ง
GB201219696D0 (en) Agents for the prevention and/or treatment of central nervous system damamge
PT3082798T (pt) Derivados de benzodioxol para uso no tratamento do défice de atenção e/ou hiperatividade
GB201209283D0 (en) Liquid treatment